Repeated subcutaneous esketamine for treatment-resistant depression: Impact of the degree of treatment resistance and anxiety comorbidity

Abstract

Background:

A large number of studies indicate that subanesthetic doses of ketamine induce a fast antidepressant effect. Limited studies have investigated the subcutaneous (SC) route, and it remains unclear for whom this treatment is most suitable.

Aims:

The aim of this study was to examine the effect on depressive symptoms of repeated subanesthetic doses of SC esketamine in unipolar and bipolar treatment-resistant depression (TRD) and clinical predictors of response.

Methods:

A retrospective analysis of 70 patients who received six SC esketamine doses weekly as an adjunctive treatment was carried out. Doses started at 0.5 mg/kg and it could be titrated up to 1 mg/kg, according to response. The primary outcome was reduction in depressive symptoms. Statistical analysis to investigate clinical predictors of effectiveness included logistic regression analysis using a dependent variable of a 50% reduction in rating scale scores at the end of treatment. Comparisons between groups were made through analysis of variance and treatment effects.

Results:

At baseline, our sample presented with severe treatment resistance in 65.7%, as assessed by the Maudsley Staging Method (MSM), and 47.1% had anxiety disorder comorbidity. The response rate was 50%. A better outcome was predicted by mild and moderate MSM scores (OR = 3.162, p = 0.041) and anxiety disorder comorbidity (OR = 3.149, p = 0.028).

Conclusions:

Our results suggest that higher levels of treatment resistance may be associated with a poor response to SC esketamine. Unlike traditional pharmacotherapies, it might benefit those with poor prognosis such as patients with depression and comorbid anxiety. Therefore, future research could investigate whether esketamine should receive a more prominent place in the treatment algorithm for TRD.

Keywords

Esketamine treatment-resistant depression subcutaneous predictors mood disorders

Get full access to this article

View all access options for this article.

References

Andrade

(2017a) Ketamine for depression, 3: Does chirality matter? J Clin Psychiatry 78: e674–e677.

Andrade

(2017b) Ketamine for depression, 4: In what dose, at what rate, by what route, for how long, and at what frequency? J Clin Psychiatry 78: e852–e857.

Berman

Cappiello

Anand

, et al. (2000) Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47: 351–354.

Canuso

Singh

Fedgchin

, et al. (2018) Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: Results of a double-blind, randomized, placebo-controlled study. Am J Psychiatry 175: 620–630.

Correia-Melo

Leal

Carvalho

, et al. (2018) Comparative study of esketamine and racemic ketamine in treatment-resistant depression: Protocol for a non-inferiority clinical trial. Medicine 97: e12414.

Correia-Melo

Leal

Vieira

, et al. (2020) Efficacy and safety of adjunctive therapy using esketamine or racemic ketamine for adult treatment-resistant depression: A randomized, double-blind, non-inferiority study. J Affect Disord 264: 527–534.

Coyle

Laws

(2015) The use of ketamine as an antidepressant: A systematic review and meta-analysis. Hum Psychopharmacol. 30: 152–163.

Daly

Singh

Fedgchin

, et al. (2018) Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: A randomized clinical trial. JAMA Psychiatry 75: 139–148.

Daly

Trivedi

Janik

, et al. (2019) Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: A randomized clinical trial. JAMA Psychiatry 08560: 1–11.

10.

Del Sant

Sarin

Magalhaes

EJM

, et al. (2020) Effects of subcutaneous esketamine on blood pressure and heart rate in treatment-resistant depression. J Psychopharmacol 34: 1155–1162.

11.

Doherty

Wajs

Melkote

, et al. (2020) Cardiac safety of esketamine nasal spray in treatment-resistant depression: Results from the clinical development program. CNS Drugs 34: 299–310.

12.

Duman

Aghajanian

Sanacora

, et al. (2016) Synaptic plasticity and depression: New insights from stress and rapid-acting antidepressants. Nat Med 22: 238–249.

13.

Fava

Rush

Alpert

, et al. (2008) Difference in treatment outcome in outpatients with anxious versus nonanxious depression: A STAR*D report. Am J Psychiatry 165: 342–351.

14.

Fekadu

Donocik

Cleare

(2018) Standardisation framework for the Maudsley staging method for treatment resistance in depression. BMC Psychiatry 18: 100.

15.

Fekadu

Wooderson

Donaldson

, et al. (2009) A multidimensional tool to quantify treatment resistance in depression: The Maudsley staging method. J Clin Psychiatry 70: 177–184.

16.

George

Gálvez

Martin

, et al. (2017) Pilot randomized controlled trial of titrated subcutaneous ketamine in older patients with treatment-resistant depression. Am J Geriatr Psychiatry 25: 1199–1209.

17.

Glue

Medlicott

Harland

, et al. (2017) Ketamine’s dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders. J Psychopharmacol. 31: 1302–1305.

18.

Glue

Neehoff

Medlicott

, et al. (2018) Safety and efficacy of maintenance ketamine treatment in patients with treatment-refractory generalised anxiety and social anxiety disorders. J Psychopharmacol 32: 663–667.

19.

Glue

Neehoff

Sabadel

, et al. (2020) Effects of ketamine in patients with treatment-refractory generalized anxiety and social anxiety disorders: Exploratory double-blind psychoactive-controlled replication study. J Psychopharmacol 34: 267–272.

20.

Harris

P A

Taylor

Thielke

, et al. (2009) Research electronic data capture (REDCap): A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 42: 377–381.

21.

Hölzel

Härter

Reese

, et al. (2011) Risk factors for chronic depression: A systematic review. J Affect Disord 129: 1–13.

22.

Hung

Liu

Yang

, et al. (2020) Comorbidity with more anxiety disorders associated with a poorer prognosis persisting at the 10-year follow-up among patients with major depressive disorder. J Affect Disord 260: 97–104.

23.

Iglewicz

Morrison

Nelesen

, et al. (2015) Ketamine for the treatment of depression in patients receiving hospice care: A retrospective medical record review of thirty-one cases. Psychosomatics 56: 329–337.

24.

Ionescu

Niciu

Richards

, et al. (2014) Pharmacologic treatment of dimensional anxious depression: A review. Prim Care Companion CNS Disord 16: PCC.13r01621.

25.

Kautzky

Dold

Bartova

, et al. (2019) Clinical factors predicting treatment resistant depression: Affirmative results from the European multicenter study. Acta Psychiatr Scand 139: 78–88.

26.

Kessler

Merikangas

Wang

(2007) Prevalence, comorbidity, and service utilization for mood disorders in the United States at the beginning of the twenty-first century. Annu Rev Clin Psychol 3: 137–158.

27.

Kroenke

Spitzer

Williams

, et al. (2007) Anxiety disorders in primary care: prevalence, impairment, comorbidity, and detection. Ann Intern Med 146: 317–325.

28.

Lecrubier

Sheehan

Weiller

, et al. (1997) The Mini International Neuropsychiatric Interview (MINI). A short diagnostic structured interview: reliability and validity according to the CIDI. European Psychiatry 12: 224–231.

29.

Loo

Gálvez

O’Keefe

, et al. (2016) Placebo-controlled pilot trial testing dose titration and intravenous, intramuscular and subcutaneous routes for ketamine in depression. Acta Psychiatr Scand 134: 48–56.

30.

McAllister-Williams

Christmas

DMB

Cleare

, et al. (2018) Multiple-therapy-resistant major depressive disorder: A clinically important concept. Br J Psychiatry 212: 274–278.

31.

McIntyre

Carvalho

Lui

, et al. (2020) The effect of intravenous, intranasal, and oral ketamine in mood disorders: A meta-analysis. J Affect Disord 276: 576–584.

32.

Montgomery

Smeyatsky

de Ruiter

, et al. (1985) Profiles of antidepressant activity with the Montgomery-Asberg depression rating scale. Acta Psychiatrica Scandinavica. Supplementum 320: 38–42.

33.

Muller

Pentyala

Dilger

, et al. (2016) Ketamine enantiomers in the rapid and sustained antidepressant effects. Ther Adv Psychopharmacol 6: 185–192.

34.

Murrough

Burdick

Levitch

, et al. (2015) Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: A randomized controlled trial. Neuropsychopharmacology 40: 1084–1090.

35.

Murrough

Perez

Pillemer

, et al. (2013) Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry 74: 250–256.

36.

Niciu

Luckenbaugh

D A

Ionescu

, et al. (2014) Clinical predictors of ketamine response in treatment-resistant major depression. J Clin Psychiatry 75: e417–e423.

37.

Ochs-Ross

Daly

Zhang

, et al. (2020) Efficacy and safety of esketamine nasal spray plus an oral antidepressant in elderly patients with treatment-resistant depression-TRANSFORM-3. Am J Geriatr Psychiatry 28: 121–141.

38.

Papadimitropoulou

Vossen

Karabis

, et al. (2017) Comparative efficacy and tolerability of pharmacological and somatic interventions in adult patients with treatment-resistant depression: A systematic review and network meta-analysis. Curr Med Res Opin 33: 701–711.

39.

Pennybaker

Niciu

Luckenbaugh

, et al. (2017) Symptomatology and predictors of antidepressant efficacy in extended responders to a single ketamine infusion. J Affect Disord 208: 560–566.

40.

Popova

Daly

Trivedi

, et al. (2019) Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: A randomized double-blind active-controlled study. Am J Psychiatry 176: 428–438.

41.

Quibell

Fallon

Mihalyo

, et al. (2015) Ketamine. J Pain Symptom Manage 50: 268–278.

42.

Rong

Park

Rosenblat

, et al. (2018) Predictors of response to ketamine in treatment resistant major depressive disorder and bipolar disorder. Int J Environ Res Public Health 15: 771.

43.

Rush

Trivedi

Wisniewski

, et al. (2006) Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report. Am J Psychiatry 163: 1905–1917.

44.

Sartori

Singewald

(2019) Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders. Pharmacol Ther 204: 107402.

45.

Singh

Fedgchin

Daly

, et al. (2016) Intravenous esketamine in adult treatment-resistant depression: A double-blind, double-randomization, placebo-controlled study. Biol Psychiatry 80: 424–431.

46.

Taylor

Landeros-Weisenberger

Coughlin

, et al. (2018) Ketamine for social anxiety disorder: A randomized, placebo-controlled crossover trial. Neuropsychopharmacology 43: 325–333.

47.

Thase

Weiller

Zhang

, et al. (2018) Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: Post hoc analyses of three placebo-controlled studies. Neuropsychiatr Dis Treat 15: 37–45.

48.

Thomas

Baker

Lind

, et al. (2018) Rapid effectiveness of intravenous ketamine for ultraresistant depression in a clinical setting and evidence for baseline anhedonia and bipolarity as clinical predictors of effectiveness. J Psychopharmacol 32: 1110–1117.

49.

Trivedi

Rush

Wisniewski

, et al. (2006) Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: Implications for clinical practice. Am J Psychiatry 163: 28–40.

50.

World Health Organization (WHO) (2020) Depression. Available at: https://www.who.int/news-room/fact-sheets/detail/depression (accessed 17 May 2020).

51.

Yang

Shirayama

Zhang

, et al. (2015) R-ketamine: A rapid-onset and sustained antidepressant without psychotomimetic side effects. Transl Psychiatry 5: e632.

52.

Zimmerman

Posternak

Chelminski

(2004) Derivation of a definition of remission on the Montgomery-Asberg depression rating scale corresponding to the definition of remission on the Hamilton rating scale for depression. J Psychiatr Res 38: 577–582.

53.

Zhou

Zheng

Liu

, et al. (2018) Neurocognitive effects of six ketamine infusions and the association with antidepressant response in patients with unipolar and bipolar depression. J Psychopharmacol 32: 1118–1126.